This trial will look for possible long-term liver damage and scarring in people taking cannabidiol by mouth.
- Lennox Gastaut Syndrome
- Dravet Syndrome
- Tuberous Sclerosis
1 Primary · 8 Secondary · Reporting Duration: Day 1, Day 365, Day 730, Day 1095, Day 1460, and Day 1825
Side Effects for
1 Treatment Group
1 of 1
150 Total Participants · 1 Treatment Group
Primary Treatment: Cannabidiol · No Placebo Group · Phase 4
Who is running the clinical trial?
Age Any Age · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any possible adverse effects to the application of Cannabidiol for therapeutic purposes?
"Backed by a Phase 4 trial, cannabidiol's safety is confidently assessed as 3 on our 1 to 3 scale." - Anonymous Online Contributor
What is the highest possible level of participation for this trial?
"Affirmative. As reported on clinicaltrials.gov, this research is still open for recruitment and began July 7th 2021. It has since been updated November 11th 2022, with a total of 150 participants to be enrolled at 29 distinct sites." - Anonymous Online Contributor
Are there any opportunities for enrolment into this trial currently available?
"Affirmative. Clinicaltrials.gov reveals that recruitment for this research project, first posted on July 7th 2021, is currently underway. 150 participants are being accepted from 29 different sites." - Anonymous Online Contributor
How widely dispersed are the experiments associated with this investigation throughout the state?
"This study is conducted across 29 different locations, including Wilmington, Richmond and Downey. To reduce travel burdens for participants, it's important to select the facility nearest you." - Anonymous Online Contributor
Are there any prior investigations of Cannabidiol's therapeutic potential?
"Currently, 79 trials exploring the efficacy of Cannabidiol are in progress. Of these studies, 16 have reached Phase 3 and there is a total of 290 sites across the globe recruiting patients to participate. The majority of clinical locations for this therapeutic agent are located in Ribeirao Preto, Sao Paulo." - Anonymous Online Contributor